

Lumito and OracleBio initiate a pilot project to explore the combination of high-sensitivity tissue imaging and advanced image analysis

Lumito AB (publ) (“Lumito” or the “Company”) and OracleBio (“OracleBio”) today announce that a joint pilot project has been initiated. The purpose of the project is to explore the combination of Lumito’s high-sensitivity platform for tissue labelling and digital imaging with OracleBio’s expertise in quantitative image analysis.

The pilot project is fully aligned with Lumito’s strategy to collaborate with established and specialised CRO companies as well as stakeholders within the tissue analysis field, to explore potential applications of the Company’s technology. By combining complementary technologies and expertise, the parties intend to evaluate possible synergies and the potential value of an integrated solution. The project is also supported by an external scientific expert in pathology, who contributes advisory support and specialist expertise.

“We are pleased to have initiated this collaboration with OracleBio, a CRO company highly specialised in analysis of digital tissue images. The pilot project gives us the opportunity to, at an early stage, explore how our respective strengths can be combined to create value in drug development”, says Sanna Wallenborg, CEO of Lumito.

“At OracleBio, we are seeing an increasing demand from Pharma clients for more detailed histological profiling of novel therapeutic targets at the tissue, cell and cell compartment level. Combining our image analysis expertise with high quality histological staining and imaging techniques enables us to provide an optimal service to our clients. By collaborating with Lumito, we gain the opportunity to work with an innovative tissue imaging technology and look forward to jointly evaluating potential applications”, says Lorcan Sherry, CSO at OracleBio.

The pilot project aims to evaluate potential future opportunities and, at this stage, does not include any financial or commercial commitments beyond the execution of the project.

For further information, please contact:

Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

About OracleBio

OracleBio is a global leader in quantitative digital pathology, providing image analysis services to Pharma and Biotech clients worldwide. Leveraging multiple software platforms, the company delivers robust data packages within a quality management framework to support all phases of R&D including pre-clinical, translational and clinical research. OracleBio’s mission is to enhance decision making within R&D by leveraging digital pathology to deliver robust data and actionable insights.

About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments

[Lumito and OracleBio initiate a pilot project to explore the combination of high-sensitivity tissue imaging and advanced image analysis](#)